|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||3.6600 - 3.8200|
|52 Week Range||1.9750 - 18.1600|
|Beta (3Y Monthly)||-0.65|
|PE Ratio (TTM)||2.17|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace than the company's previous modelling had expected. The maker of drugs that treat opioid addiction posted a pretax profit of $89 million in the second quarter ended June 30 from $78 million a year earlier. Revenue fell nearly 20% to $215 million in the quarter due to the expected decline in market share for Suboxone, but Indivior reaffirmed that it expects 2019 revenue to be between $670 million and $720 million.
SLOUGH, England and RICHMOND, Va. , July 31, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half 2019 results press release and investor supplement are now available via the ...
The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.
A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.
(Bloomberg Opinion) -- Reckitt Benckiser Plc has taken the medicine.The company has settled with U.S. authorities to resolve a long-running investigation into the sale and marketing of an opioid addiction treatment by former subsidiary Indivior Plc.The payment is a big one: $1.4 billion. That far exceeds the $400 million provision it had set aside. But it draws a line under an issue that had threatened to derail a potential break-up of the maker of Cillit Bang cleaner and Durex condoms. Reckitt denied any wrongdoing, and said the settlement was in the best interests of the company and investors.It certainly isn’t helpful to the company’s balance sheet – it will increase net debt to 2.8 times Ebitda at the end of this year, according to Martin Deboo, analyst at Jefferies. That further constrains the company’s ability to participate in industry M&A. However, the shares rose about 3% on Thursday. This indicates the outcome was no worse than feared. Analysts at Bernstein had suggested back in April, when Indivior was indicted by the Justice Department, that the worst case scenario could be $1.5 billion.What’s more, the settlement does not bar Reckitt from participating in U.S. government programs, such as one that provides free baby milk. Losing this would have been extremely damaging to the infant nutrition business that Reckitt added when it acquired Mead Johnson.But even more important is that by resolving the issue, Reckitt can now move forward unencumbered. Outgoing chief executive Rakesh Kapoor deserves credit for finalizing the matter before his departure, leaving a clean slate to his successor, Laxman Narasimhan.The potential liabilities threatened to hamper the logical conclusion of Reckitt’s separation into two divisions, one focused on household products, and the other on consumer health.Narasimhan will still face significant challenges when he arrives shortly. Chief among them is reinvigorating sales growth, which stalled under his predecessor. He must also determine whether Reckitt's industry-leading margins can be sustained, or whether some profitability must be sacrificed to step up investment and turbo charge sales growth.But at least he can now pursue a break-up – assuming he wants to – without the U.S. legal risks hanging over him.To contact the author of this story: Andrea Felsted at firstname.lastname@example.orgTo contact the editor responsible for this story: Jennifer Ryan at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
SLOUGH, England and RICHMOND, Va. , July 11, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced revised expectations for FY 2019 net revenue and net income following stronger than expected H1 ...
The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film. The deal came after Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.
Britain's Reckitt Benckiser will pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior. Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) to resolve the investigation into a business that was wholly demerged from the company in 2014. The U.S. Justice Department had accused Indivior of illegally boosting prescriptions for the opioid addiction treatment, called Suboxone Film.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Indivior PLC (“Indivior” or “the Company”) (OTC: INVVY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Indivior and its executives participated in a scheme to increase prescriptions of Suboxone Film.
NEW YORK, NY / ACCESSWIRE / June 24, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Indivior PLC ("Indivior" or the "Company") ...
NEW YORK, June 24, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
NEW ORLEANS, June 23, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large.
NEW YORK, June 22, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Indivior PLC (OTC: INVVY) from March 10, 2015 through.
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until June 24, 2019 to file lead plaintiff applications in a securities class action lawsuit against Indivior PLC (INVVY). Investor losses must relate to purchases of the Company’s securities between March 10, 2015 and April 9, 2019.
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Indivior PLC (INVVY) from March 10, 2015 through April 9, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Indivior investors under the federal securities laws. To join the Indivior class action, go to http://pawarlawgroup.com/cases/indivior-plc/ or call Vik Pawar, Esq.